Biochemical Markers of Bone Fragility in Patients With Diabetes
Open Access
- 8 May 2023
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (10) , e923-e936
Abstract
Context The risk of fragility fractures is increased in both type 1 and type 2 diabetes. Numerous biochemical markers reflecting bone and/or glucose metabolism have been evaluated in this context. Objective This review summarizes current data on biochemical markers in relation to bone fragility and fracture risk in diabetes. Methods A group of experts from the International Osteoporosis Foundation and European Calcified Tissue Society reviewed the literature focusing on biochemical markers, diabetes, diabetes treatments, and bone in adults. Results Although bone resorption and bone formation markers are low and poorly predictive of fracture risk in diabetes, osteoporosis drugs seem to change bone turnover markers (BTMs) in diabetics similarly to nondiabetics, with similar reductions in fracture risk. Several other biochemical markers related to bone and glucose metabolism have been correlated with bone mineral density and/or fracture risk in diabetes, including osteocyte-related markers such as sclerostin, glycated hemoglobin A1c (HbA1c) and advanced glycation end products, inflammatory markers, and adipokines, as well as insulin-like growth factor-1 and calciotropic hormones. Conclusion Several biochemical markers and hormonal levels related to bone and/or glucose metabolism have been associated with skeletal parameters in diabetes. Currently, only HbA1c levels seem to provide a reliable estimate of fracture risk, while BTMs could be used to monitor the effects of antiosteoporosis therapy.Keywords
This publication has 187 references indexed in Scilit:
- A Study of Bone Mineral Density and Its Determinants in Type 1 Diabetes MellitusJournal of Osteoporosis, 2013
- Trabecular bone histomorphometry in humans with Type 1 Diabetes MellitusBone, 2012
- The effects of adiponectin and leptin on changes in bone mineral densityOsteoporosis International, 2011
- Circulating osteocalcin level is associated with improved glucose tolerance, insulin secretion and sensitivity independent of the plasma adiponectin levelOsteoporosis International, 2011
- Bone structure and turnover in type 2 diabetes mellitusOsteoporosis International, 2011
- Adipokines in inflammation and metabolic diseaseNature Reviews Immunology, 2011
- The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled TrialCalcified Tissue International, 2010
- Relationships among serum receptor of nuclear factor-κB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineraldensity in postmenopausal womenMenopause, 2009
- High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesisBone, 2008
- Nontraumatic Fracture Risk With Diabetes Mellitus and Impaired Fasting Glucose in Older White and Black AdultsArchives of internal medicine (1960), 2005